Dan Barouch

May 17, 2024 | onlinelibrary.wiley.com | Huub C Gelderblom |Lawrence Corey |Dan Barouch

The number of new HIV acquisitions globally has declined, but not rapidly enough to meet the 2030 targets set by UNAIDS and the United Nations Sustainable Development Goals (SDGs) [1, 2]. Despite intense efforts such as those to support the UNAIDS 95-95-95 targets and to expand the availability of oral pre-exposure prophylaxis (PrEP), progress in primary prevention of HIV acquisition has lagged.

Mar 27, 2024 | biorxiv.org | Sam Turner |Gayatri Amirthalingam |Dalan Bailey |Dan Barouch

AbstractThe highly mutated SARS-CoV-2 variant, BA.2.86, and its descendants are now the most frequently sequenced variants of SARS-CoV-2. We analyze antibody neutralization data from eight laboratories from the UK, USA, Denmark, and China, including two datasets assessing the effect of XBB.1.5 vaccines, to determine the effect of infection and vaccination history on neutralization of variants up to and including BA.2.86, and produce antibody landscapes to describe these neutralization profiles.

Feb 14, 2023 | nature.com | Etsuro Nanishi |Hyuk-Soo Seo |Kijun Song |Andrew Xu |Soumik Barman |Blake M Hauser | +8 more

AbstractDevelopment of SARS-CoV-2 vaccines that protect vulnerable populations is a public health priority. Here, we took a systematic and iterative approach by testing several adjuvants and SARS-CoV-2 antigens to identify a combination that elicits antibodies and protection in young and aged mice. While demonstrating superior immunogenicity to soluble receptor-binding domain (RBD), RBD displayed as a protein nanoparticle (RBD-NP) generated limited antibody responses.